Literature DB >> 1929335

Effects of antimicrobial agents on survival of Mycobacterium avium complex inside alveolar macrophages obtained from patients with human immunodeficiency virus infection.

D M Yajko1, P S Nassos, C A Sanders, W K Hadley.   

Abstract

Measurements of the activities of antimicrobial agents against the Mycobacterium avium complex (MAC) usually do not take into consideration the intracellular location of the organism. A recent study using mouse macrophage continuous cell line J774 (D. M. Yajko, P.S. Nassos, C. A. Sanders, and W. K. Hadley, Am. Rev. Respir. Dis. 140: 1198-1203, 1989) showed that certain combinations of antimicrobial agents are able to kill MAC inside macrophages and suggested that the J774 cell line could be used as a model for screening of drugs for intracellular activity against MAC. As a test of the validity of this model, alveolar macrophages were isolated from the bronchoalveolar lavages of 36 patients who had AIDS or an AIDS-related condition or were considered to be at risk for AIDS. The macrophages were infected with MAC and then treated with a drug or drug combination for 48 to 72 h. Survival of MAC was measured over time in drug-treated macrophages and untreated control macrophages. No single drug or two-drug combination that was tested was able to cause a decrease in the survival of every one of the MAC strains used in the study. However, several three-drug combinations that had been shown to cause a decrease in survival of all MAC strains inside J774 cells also caused a decrease in survival of all MAC strains inside alveolar macrophages from patients. The good agreement between these results and those obtained previously with J774 cells gives further evidence of the usefulness of the simpler J774 model for screening of drugs for intracellular activity against MAC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929335      PMCID: PMC245230          DOI: 10.1128/AAC.35.8.1621

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Killing by antimycobacterial agents of AIDS-derived strains of Mycobacterium avium complex inside cells of the mouse macrophage cell line J774.

Authors:  D M Yajko; P S Nassos; C A Sanders; W K Hadley
Journal:  Am Rev Respir Dis       Date:  1989-11

2.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

3.  Ethambutol: a key for Mycobacterium avium complex chemotherapy?

Authors:  G Källenius; S B Svenson; S E Hoffner
Journal:  Am Rev Respir Dis       Date:  1989-07

4.  Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium.

Authors:  S E Hoffner; S B Svenson; G Källenius
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

5.  Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome.

Authors:  D M Yajko; J Kirihara; C Sanders; P Nassos; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents.

Authors:  D M Yajko; P S Nassos; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

7.  Host defense against Mycobacterium-avium complex.

Authors:  S Schnittman; H C Lane; F G Witebsky; L L Gosey; M D Hoggan; A S Fauci
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

8.  In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex.

Authors:  S E Hoffner; M Kratz; B Olsson-Liljequist; S B Svenson; G Källenius
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

9.  Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects.

Authors:  L B Heifets; M D Iseman; P J Lindholm-Levy
Journal:  Am Rev Respir Dis       Date:  1988-03

10.  Susceptibility of Mycobacterium avium complex to various two-drug combinations of antituberculosis agents.

Authors:  G Ozenne; A Morel; J F Menard; C Thauvin; J P Samain; J F Lemeland
Journal:  Am Rev Respir Dis       Date:  1988-10
View more
  5 in total

Review 1.  The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections.

Authors:  G W Amsden; C A Peloquin; S E Berning
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 2.  Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.

Authors:  C A Peloquin
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

3.  Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals.

Authors:  D M Yajko; P S Nassos; C A Sanders; P C Gonzalez; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium.

Authors:  L Fattorini; B Li; C Piersimoni; E Tortoli; Y Xiao; C Santoro; M L Ricci; G Orefici
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 5.  Challenges of NTM Drug Development.

Authors:  Joseph O Falkinham
Journal:  Front Microbiol       Date:  2018-07-18       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.